FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to new methods for the treatment in a subject of an infection caused by a hepatitis B virus (hereinafter – HBV); it can be used in medical practice. The invention discloses the possibility of carrying out a combination therapy of HBV infection, using an agonist of a tumor necrosis factor receptor superfamily (TNFRSF) and interferon (IFN), wherein the specified therapeutical agents can be used both separately in the form of a composition and as part of fused protein.
EFFECT: such combination therapy is aimed at the reduction in severity of one or more symptoms of HBV infection caused in a subject.
18 cl, 4 tbl, 19 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ASSAY FOR MEASURING CELL-MEDIATED IMMUNORESPONSIVENESS | 2010 |
|
RU2605381C2 |
| PREVENTIVE OR THERAPEUTIC AGENT AGAINST VIRAL DISEASE | 2007 |
|
RU2433827C2 |
| USE OF STIMULANT FOR ANALYZING ACTIVITY OF IMMUNE CELLS | 2020 |
|
RU2822517C2 |
| METHODS OF TREATING ALLERGIC DISEASES | 2011 |
|
RU2587061C2 |
| METHODS FOR INCREASING EFFECTIVENESS OF ANTITUMOUR IMMUNE RESPONSE | 2015 |
|
RU2689162C2 |
| BI- OR MULTISPECIFIC POLYPEPTIDES BINDING IMMUNE EFFECTOR CELL SURFACE ANTIGENS AND HBV ANTIGENS FOR TREATMENT OF BV INFECTIONS AND ASSOCIATED CONDITIONS | 2014 |
|
RU2671089C2 |
| IMMUNOSTIMULATING COMBINATION FOR PREVENTION AND TREATMENT OF HEPATITIS C | 2006 |
|
RU2431499C2 |
| HETEROCYCLIC IMMUNOMODULATORS AS INHIBITOR OF IMMUNE RESPONSE CHECKPOINTS PDL1 | 2020 |
|
RU2824127C2 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| TEST SYSTEM FOR DETERMINATION OF INTERFERON, IL23 INTERLEUKINE AND MXA ANTI-VIRUS PROTEIN RNA | 2016 |
|
RU2627179C1 |
